Second-line treatment for primary central nervous system lymphoma. - Wikidata - awgldk - TriplyDB

Second-line treatment for primary central nervous system lymphoma.

Second-line treatment for primary central nervous system lymphoma.

http://www.wikidata.org/entity/Q33535184

about

18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas Treatment options for central nervous system lymphomas in immunocompetent patients.Late relapse in primary central nervous system lymphoma: clonal persistence Temozolomide as salvage treatment in primary brain lymphomas.Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.Primary CNS lymphoma: a clinician's guide.Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Salvage therapy for refractory AIDS-related primary central nervous system lymphoma.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.Primary CNS Lymphoma.

P2860

Q30654615-09E3D264-C38F-4A25-97E4-989F9F2CAFEA Q33347138-E3D6783C-A6EE-4447-82A8-40F97AC37FF4 Q33396041-27131C96-E8B3-4A44-9CA5-8E5D80FBBFA5 Q33427856-AA4BF299-FD58-42E6-A40C-53F086138AFC Q33510785-F250D735-705C-4E4E-B33B-D7976C4360C9 Q34977369-0CAF4262-794F-4B48-8541-11D24287F710 Q36610071-93544882-AAFE-49CE-96FD-0515E5599A96 Q36805893-B3A9C076-86D3-49C3-896C-65D3020B1814 Q37183305-B3BAE9C1-2E6B-4938-8FF7-E0BF6D5FCCDA Q38053442-2121D8FB-D91C-4ADB-B5D8-0EB362D13766 Q38741324-1BD1F75A-52D4-4D4E-8A46-6D8467DD58AC Q40196257-B392A611-79F4-4DEF-B10A-7B5286C7B402 Q41139081-7E54A6B7-626D-4979-8DC4-52715BD7FF48 Q42632859-EDD67238-ED43-4039-AF81-20F3DC5AD5A4 Q47692369-92EE379F-DFC5-4FD6-8EEB-14D720DB8220 Q48114320-688615A5-007E-4A32-8838-2A0178CEC819 Q48132084-04678C3E-1D9F-44ED-B38B-6428423AD027 Q51841565-87C6FEAB-FA1D-487C-B511-60B9775603EA

P2860

Second-line treatment for primary central nervous system lymphoma.

http://www.wikidata.org/entity/Q33535184

description

1999 nî lūn-bûn

@nan

1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Second-line treatment for primary central nervous system lymphoma.

@ast

Second-line treatment for primary central nervous system lymphoma.

@en

Second-line treatment for primary central nervous system lymphoma.

@nl

type

label

Second-line treatment for primary central nervous system lymphoma.

@ast

Second-line treatment for primary central nervous system lymphoma.

@en

Second-line treatment for primary central nervous system lymphoma.

@nl

prefLabel

Second-line treatment for primary central nervous system lymphoma.

@ast

Second-line treatment for primary central nervous system lymphoma.

@en

Second-line treatment for primary central nervous system lymphoma.

@nl

P1433

Q33535184-860917B3-0521-46F1-A432-B83B935F8C57

P1476

Q33535184-CFC9A42D-86D6-42C3-B87C-B5F7F2483490

P2093

Q33535184-17192AE0-E84F-44ED-8CAD-75210F5EDC23

Q33535184-2B27C2EA-9435-4751-9EF5-E76FFCDBD91C

Q33535184-CA1DA5BA-6F08-4A42-90A6-3FB527675434

P2860

Q33535184-1AACEA74-C087-481D-9FE2-6CB536ADFE2F

Q33535184-2AA930EC-58EC-43EA-9210-CB2ED55626EF

Q33535184-2AABE232-055F-4A05-B381-671B218E9708

Q33535184-3189532C-59A7-46C3-BF9F-944286A09A59

Q33535184-3B7A8926-53B1-4995-9B23-1B245B33B022

Q33535184-40DD06DB-D916-483A-BD41-A2B592B0439D

Q33535184-5016378F-E319-4C2F-8D87-B5DA5614CFF6

Q33535184-5A51017C-19B8-4921-8064-DF203A59D962

Q33535184-67D6BC01-65E7-4664-B6EB-F52AC5271CA4

Q33535184-6F664D16-E806-42E7-80FC-1EE252BF44D0

P2888

Q33535184-D2E3B16D-1DCD-4785-8AEC-84F863C4050A

P304

Q33535184-31FBDEAA-4644-4E33-A390-3B838091BF6F

P31

Q33535184-045883E6-5853-44EB-8A48-DE80448DA5DC

Q33535184-7AFC8ECA-6832-4069-B923-2ABCF64C4659

P356

Q33535184-24631E4B-5F82-4BE2-8734-588614ECCAAB

P407

Q33535184-76CD8F34-82AA-403F-8219-EDB02A244A81

P433

Q33535184-68FA6877-65D7-4275-9618-E60B09233A6C

P478

Q33535184-7E51BE37-C5EC-413F-8C3E-99F4ED13C931

P577

Q33535184-F328CACE-318F-41A7-9169-C6BCC768F70D

P5875

Q33535184-7FB56A7F-AF2E-4C82-B9E8-9357CF149BB4

P6179

Q33535184-644B7A71-DF68-4741-9CC6-0F7AC16AD24D

P698

Q33535184-455FBC2D-743F-4026-9386-7099FBFFF74D

P921

Q33535184-0DF3C933-929D-42D7-9FC2-42568492A67E

Q33535184-A4EC2356-E104-4560-8B0A-1A1F43AC2D1D

Q33535184-D183B069-866B-4326-BA29-EE29CEB22FBD

P932

Q33535184-B917763A-0F48-4114-8A9B-6550E7AD009C

P356

P1433

British Journal of Cancer

P1476

Second-line treatment for primary central nervous system lymphoma.

@en

P2093

Ferreri AJ

http://www.w3.org/2001/XMLSchema#string

Reni M

http://www.w3.org/2001/XMLSchema#string

Villa E

http://www.w3.org/2001/XMLSchema#string

P2860

Primary central nervous system lymphoma

Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO.

Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature.

Primary non-Hodgkin's lymphoma of the brain. A review.

Primary lymphoma of the central nervous system. Computerized tomography scan characteristics and treatment results for 12 cases.

Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).

Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature.

Primary central nervous system lymphoma in immunocompetent patients.

Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature.

P2888

P304

530-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6690083

http://www.w3.org/2001/XMLSchema#string

P407

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13262890

http://www.w3.org/2001/XMLSchema#string

P6179

1041883342

http://www.w3.org/2001/XMLSchema#string

P698

10027325

http://www.w3.org/2001/XMLSchema#string

P921

non-Hodgkin lymphoma

central nervous system neoplasm

atypical teratoid rhabdoid tumor

P932

2362452

http://www.w3.org/2001/XMLSchema#string